Our strategy

All over the world, psychiatric and neurological disorders are a growing burden, not only for individuals, but for families and societies as well. At Lundbeck, we strive for global leadership in psychiatry and neurology by improving the lives of patients. With Lundbeck’s new strategy, we will focus our efforts throughout the value chain in order to create value for patients, society and our shareholders.

How we create value
Lundbeck has developed a new strategy in order to increase the company’s performance and value creation. The strategy consists of a simple framework with three elements. Our vision describes what we strive for, our principles guide our actions and our strategic objectives define the strategic focus for decisions and execution of the strategy in the years to come.


Strategic objectives
Lundbeck’s management has defined five strategic objectives, which describe the focus for decisions and execution of the strategy in the years to come: four disease areas, innovation, globalization, profitability and organization. 

Four disease areas
We will strive for leadership in the treatment of depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

In the coming years, we have decided to focus our efforts on the four disease areas where we believe Lundbeck can lead the innovation of improved treatments. All four disease areas are characterized as areas with huge unmet medical needs, and where Lundbeck has expertise and competitive advantages throughout the value chain. By focusing our efforts on areas where we have the most expertise, we believe that we will be able to create significant value for patients, society and shareholders. 

For other psychiatric and neurological disorders, Lundbeck will have an opportunistic approach if compounds developed to treat the four focus diseases also can help patients with related psychiatric and neurological disorders. However, Lundbeck will not expand the existing commercial portfolio through external opportunities.

We will develop innovative treatments that address unmet patient needs.

Lundbeck has during the last 70 years conducted research in psychiatric and neurological disorders and is today among the leading pharmaceutical companies within neuroscience research. The core of the value we create is derived from the better treatments we discover, develop and distribute. Today, treatments for psychiatric and neurological disorders are primarily symptomatic, but we believe that in the future we will be able to discover new pharmaceuticals targeting the underlying mechanisms of these disorders. This approach allows us to treat the symptoms more effectively and also potentially to alter the courses of the disorders.

We will expand and optimize our global organization.

Today, we have our own organization in more than 50 countries and have made our pharmaceutical treatments available in more than 100 countries. With a global presence, we are able to increase the value of the pharmaceuticals we commercialize. Our ability to provide treatments to patients in a country is dependent on a robust healthcare system. We expect to create value by working with societies around the world, improving access for patients to better treatments and by balancing and expanding our global organization accordingly.

We will grow our business with a strong focus on profitability created by independent development and commercialization of future products.

The ability to create a growing business and deliver profitable results is what makes Lundbeck able to improve treatments for patients, offer an attractive return to our shareholders and contribute to the societies we operate in.

Lundbeck will be a specialized company with strong cross-functional collaboration.

Lundbeck is a mid-sized pharmaceutical company constantly optimizing the organization in order to generate value. In order to regain the company’s profitability and position the company for future success, Lundbeck announced in 2015 the company-wide restructuring programme.


Lundbeck strives for global leadership in psychiatry and neurology by improving the lives of patients.

Our principles

Our principles are based on Lundbeck’s unique culture and guide the daily decisions and behaviour of people in the company.


We are focused on innovating treatments for depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease while creating value for all our stakeholders.


We are passionate about helping patients and communities affected by psychiatric and neurological disorders.


We are responsible and overcome challenges by demonstrating respect, open-mindedness and integrity.

Annual Report 2015

Read our Annual Report 2015.


Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.